The cytoplasmic immunophilin FKBP12, a 12 kDa FK506-binding protein, has been shown to act as an inhibitor for transforming growth factor-(TGF-) signaling. FKBP12 binds to the glycine-and serine-rich motif (GS motif) of the TGF-type I receptor, and functions as a secure switch to prevent the leaky signal. Upon stimulation with ligand, FKBP12 is released from the receptor to fully propagate the signal. We found that activin, a member of TGFsuperfamily, also induced the dissociation of FKBP12 from the activin type I receptor (ALK4). However, we observed that the released FKBP12 associates again with the receptor a few hours later. FKBP12 also interacted with another inhibitory molecule of activin signal, Smad7, in an activin-dependent manner, and formed a complex with Smad7 on the type I receptor. FK506, a chemical ligand for FKBP12, which dissociates FKBP12 from the receptor, decreased the interaction between Smad7 and Smad ubiquitin regulatory factor 1 (Smurf1). FK506 also inhibited the ubiquitination of the type I receptor by Smurf1. These findings indicate a new inhibitory function of FKBP12 as an adaptor molecule for the Smad7-Smurf1 complex to regulate the duration of the activin signal.
Introduction
Activin was originally discovered as a regulator of reproduction. Activin induces secretion of folliclestimulating hormone (FSH) from the anterior pituitary, whereas inhibin produced by the gonads in response to FSH acts at the pituitary to regulate the effects of activin. Activin and inhibin belong to the transforming growth factor-(TGF-) superfamily, which includes TGF-s and bone morphogenetic proteins (BMPs). These ligands regulate a number of biological processes, such as cell proliferation, differentiation, apoptosis, inflammatory processes, and cell migration (Kingsley 1994 , Tsuchida 2004 , Phillips 2005 . They bind to constitutively active type II Ser/Thr kinase receptors on the cell surface, and these receptors directly phosphorylate the glycine-and serine-rich region (GS motif) of the type I receptors. This phosphorylation activates the type I receptor, which proceeds the signal to the intracellular signal mediators known as Smads , Massagué 2000 , ten Dijke & Hill 2004 . Smad2 and Smad3 mediate TGF-and activin signaling, while Smad1, Smad5, and Smad8 propagate BMP signals. These Smad proteins are phosphorylated at their C-terminals by activated type I receptors, form complexes with Smad4, and regulate transcription in the nucleus through interactions with other transcription factors. The inhibitory Smads, Smad6 and Smad7, are induced by stimulation with ligands to inhibit signaling (Hayashi et al. 1997 , Nakao et al. 1997 , Itoh et al. 1998 ). Smad7 associates with activated type I receptors, and prevents phosphorylation of regulatory (R)-Smads by these receptors (Souchelnytskyi et al. 1998) . Smad7 also recruits Smad ubiquitin regulatory factor 1 (Smurf1) to the type I receptors to promote ubiquitination of the receptors (Kavsak et al. 2000 .
FKBP12 is a cytoplasmic protein that binds to the immunosuppressant drugs, Tacrolimus (FK506) and rapamycin, with high affinity (Schreiber 1991 . FKBP12 has been demonstrated to interact with the two major intracellular calcium channels, ryanodine receptor and inositol 1,4,5-triphosphate receptor (IP 3 R) as a physiological subunit of the channel protein complexes (Jayaraman et al. 1992 , Cameron et al. 1995 , Schiene-Fischer & Yu 2001 . Dissociation of FKBP12 from these channels influences physiological calcium flux from the channels (Steinmann et al. 1991 , Clipstone & Crabtree 1992 . In addition, FKBP12 plays a role as an anchor for the calcium-activated phosphatase, calcineurin, to the tri-complex with IP 3 R and modulates the phosphorylation state of the receptor (Cameron et al. 1997) .
FKBP12 also regulates TGF-superfamily signal transduction (Wang et al. 1994 , Okadome et al. 1996 , Chen et al. 1997 , Wang & Donahoe 2004 . FKBP12 interacts with the type I receptors of the TGF-family members, including BMP and activin (Wang et al. 1996 , Kurozumi et al. 1998 . FKBP12 binds to the GS domain in the cytoplasmic region of TGF-type I receptor and represses the signal. Overexpression of FKBP12 strongly inhibits TGF-signal in Mv1 Lu cells. On the other hand, the dissociation of FKBP12 from the type I receptor by FK506 derivatives enhances the TGF-signal. Indeed, upon ligand stimulation, phosphorylation of serine residues of the GS domain of type I receptors by TGF-type II receptor dissociates FKBP12 from the type I receptors to fully propagate the signals (Huse et al. 2001) . These findings indicate that FKBP12 functions as a secure switch for the leaky signal in the absence of ligands. However, there are several contradictory reports. Physiological studies in FKBP12-deficient mice demonstrated that FKBP12 is dispensable for TGF--mediated signaling, but modulates the calcium release activity of both skeletal and cardiac ryanodine receptors (Shou et al. 1998) . The biochemical analysis of mouse primary embryonic fibroblasts and thymocytes from the gene targeting mice failed to show any unique physiological role of FKBP12 in TGF-signaling (Bassing et al. 1998 , Shou et al. 1998 . The discrepancy between these reports may be explained by the existence of the related protein, FKBP12·6, and the other FKBP proteins (Gothel & Marahiel 1999) .
In the present study, we investigated the roles of FKBP12 on activin signaling. We have shown that FKBP12 transiently dissociates from activin type I receptor upon ligand stimulation, but a few hours later FKBP12 associates again with the receptor. We have demonstrated that FKBP12 forms a complex with Smad7 on the activated type I receptor, and recruits the E3 ubiquitin ligase, Smurf1, to the receptor to promote its ubiquitination. Our data suggest a novel inhibitory function of FKBP12 as the adaptor molecule of the receptor in activin signaling.
Materials and methods

Cell culture
Chinese hamster ovary (CHO) cells were cultured in -modified Eagle's medium supplemented with 10% fetal bovine serum (FBS), -glutamine, and penicillin/ streptomycin at 37 C, in a 5% CO 2 atmosphere. Human embryonic kidney 293 (HEK293) cells and 293T cells were cultured in Dulbecco's modified Eagle's medium containing 10% FBS -glutamine, and penicillin/streptomycin.
Plasmid constructions
The entire coding region of human FKBP12 was amplified by PCR, and subcloned into N-terminally tagged vector, pcDNA3-Flag or pcDNA3-6 myc. The mutant derivative of FKBP12 was generated by PCR with mismatch sense and antisense primers. The products were verified by DNA sequencing. Human constitutive active ALK4 (caALK4) was subcloned into pcDNA3 containing five repeats of the myc epitope sequence. N-terminally Flag-tagged human Smad6 and Smad7 in pcDNA3 were constructed by a similar PCR-based approach. For mammalian two-hybrid interaction assays, pBIND-FKBP12, pACT-ALK4, and pACT-Smad7 were constructed by subcloning of the full-length cDNAs into pBIND vector, which contains the yeast GAL4 DNA binding domain upsteam of a multiple cloning region or pACT vector, which contains the herpes simplex virus VP16 activation domain upstream of a multiple cloning region (Promega). The plasmids for the bacterial expression of glutathione-Stransferase (GST)-Smad7, GST-Smad7N (2-261 amino acids) and GST-Smad7C (204-426 amino acids) were generous gifts from Dr J Ericsson (Gronroos et al. 2002) . The GST-fusion proteins were expressed in an Escherichia coli strain, BL21 (DE3) and purified on glutathione sepharose beads (Amersham).
Cell transfections and luciferase assays
Transient transfection was performed with Transfast (Promega) according to the manufacturer's protocols. Transfection was also performed with calcium phosphate precipitation as previously described (Kurisaki et al. 2003) . For luciferase assays, CHO cells were seeded in 24-well plates and transfected with the Transfast reagent (Promega). At 24 h after transfection, the cells were treated with 50 ng/ml activin A and/or 250 nM FK506 (Fujisawa Pharmaceutical Co., Tokyo, Japan) for 24 h, and then extracted in a lysis buffer (25 mM glycylglycine, pH 7·8, 15 mM MgSO 4 , 4 mM EGTA, and 1% Triton X-100). The luciferase activity was measured and normalized to the -galactosidase activity, as described previously (Shoji et al. 2000) .
Mammalian two-hybrid assay
The mammalian two-hybrid assay was performed using the CheckMate Mammalian Two-Hybrid System (Promega) according to the manufacturer's protocol. In brief, CHO cells were transfected with the plasmids of interest, a cytomegalovirus promoter-driven -gal (CMV--gal) and a reporter plasmid, pG5 luc, which drives the luciferase gene under the control of the GAL4-responsive promoter. Luciferase activity was measured and normalized to the -galactosidase activity as described previously (Tsuchida et al. 1995 , Shoji et al. 2000 .
Immunoprecipitation and immunoblotting
HEK293 cells transfected with plasmids were harvested in lysis buffer A (20 mM Tris-HCl, pH7·4, 150 mM NaCl, 1% (w/v) Nonidet P-40, 1% (v/v) aprotinin, and 1 mM phenylmethylsulfonyl fluoride) at 24 h after transfection. After centrifugation, the lysates were incubated with first antibodies at 4 C overnight, and then incubated with protein G agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA, USA). For His-tagged ALK4, cell lysates were incubated with Ni-NTA agarose (Invitrogen) at 4 C for 2 h. The precipitated beads were washed with the lysis buffer extensively, and subjected to SDS-PAGE. The separated proteins were transferred to nitrocellulose membranes, and blotted with first antibodies followed by incubation with horseradish peroxidase-conjugated second antibodies. Labeled proteins were detected by chemiluminescence (ECL or ECL-Plus; Amersham). The antibodies used for immunoprecipitation and immunoblotting were as follows: mouse monoclonal antibodies including anti-myc (9E11; Neo Markers), anti-Flag (M2; Sigma), anti-HA (12CA5; Roche), and anti-His (Penta his; QIAGEN).
In vitro interaction assays
For in vitro interaction studies, HEK293T cells were transfected with Flag-FKBP12, wild-type (wt) ALK4-His or 5 myc-caALK4. Cells were lysed in lysis buffer A, and incubated with purified GST-Smad7 fusion proteins immobilized on glutathione beads at 4 C for 2 h. The beads were washed with the lysis buffer and then subjected to SDS-PAGE followed by western blotting as described above.
Results
Interaction of FKBP12 with activin type I receptor is dynamically regulated
FKBP12 functions as a secure switch for TGF-signals, and has been shown to be released from type I receptors upon ligand stimulation (Chen et al. 1997 , Huse et al. 2001 . We investigated this interaction over a long-term period. To do this, 293T cells were transfected with Flag-FKBP12, activin type II receptor (ActRIIA), and His-tagged activin type I receptor (His-ALK4). The cells were stimulated with activin for various time-periods, and FKBP12 bound to ALK4 was analysed by pull-down assays with Ni-NT agarose beads (Fig. 1) . FKBP12 was gradually dissociated from ALK4 up to 1 h after stimulation with activin. However, the amount of FKBP12 bound to ALK4 was increased later. At 6 h after ligand treatment, a similar amount of FKBP12 bound to the receptor was observed as that prior to stimulation. This observation raised the possibility that FKBP12 works not only as a secure switch prior to ligand stimulation but also controls the signaling after long-term stimulation with activin.
FKBP12 inhibits activin signals
To confirm the inhibitory effect of FKBP12 on activin signaling, we performed reporter assays using an activin-responsive luciferase reporter, p3TP-Lux, in CHO cells. Activin induced a 3TP-Lux transcriptional response in CHO cells ( Fig. 2A) . Overexpression of FKBP12 suppressed activin-induced luciferase activity in a dose-dependent manner. Under these conditions, the endogenous mRNA levels of receptors were not affected (data not shown). Treatment of cells with FK506, a chemical ligand for FKBP12 that can release FKBP12 from the type I receptor in TGF-signaling, enhanced HEK293T cells transfected with Flag-FKBP12, His-ALK4 and ActRII were stimulated with activin A (100 ng/ml) for various periods as indicated. Cell lysates were subjected to pull-down assay (Pd) with Ni-beads followed by immunoblot analysis using anti-Flag antibody. Total lysate was immunoblotted (IB) with anti-His or anti-Flag antibodies.
the luciferase activity 1·5-fold in the absence of activin (data not shown), as previously demonstrated in TGFsignaling (Wang et al. 1996) . These results indicated that endogenous FKBP12 functions as a secure switch in activin signaling in the absence of ligand. On the other hand, in the presence of activin, the increase in the luciferase activities by FK506 was not dramatic, but still a substantial effect of this drug (1·1-fold) was observed (data not shown). These results further support the idea that FKBP12 also has an inhibitory effect on activin signaling in the presence of ligand.
FKBP12 synergistically inhibits activin transcriptional response with Smad7
Since Smad7 also inhibits activin signaling, we next analysed the inhibitory effect of FKBP12 and Smad7 on activin signaling. CHO cells transfected with FKBP12 and Smad6 or Smad7 were subjected to the luciferase assay. FKBP12 alone repressed the luciferase activity induced by activin in a dose-dependent manner (Fig. 2B) . Overexpression of Smad7 inhibited the activin signal as reported previously (Liu et al. 2002) . When FKBP12 was coexpressed with Smad7, FKBP12 further repressed the signal in a dose-dependent manner. Interestingly, this co-operative effect of FKBP12 with Smad7 was not observed when Smad6 was coexpressed with FKBP12.
FKBP12 physically interacts with Smad7 in the presence of activin
In order to explain this result, we hypothesized that FKBP12 may physically interact with Smad7 and repress activin signaling co-operatively. To test this possibility, we analysed the interaction with a mammalian two-hybrid assay. When CHO cells were transfected with Gal4-FKBP12, VP16-ALK4, and the Gal4-luciferase reporter, the luciferase activity was 9-fold higher than with Gal4-FKBP12 alone, indicating that interaction between FKBP12 and ALK4 was detectable with this mammalian two-hybrid system (Fig. 3A) . When Smad7 was coexpressed with FKBP12, the luciferase activity was six times higher than with FKBP12 alone. However, coexpression of Smad6 with FKBP12 gave much weaker activity, suggesting that FKBP12 interacts more strongly with Smad7 than with Smad6. This interaction was further confirmed by a coimmunoprecipitation assay. HEK293 cells transfected with 6 myc-FKBP12 and Flag-Smad7 were lysed, and subjected to immunoprecipitation analysis as in Fig. 3B . Smad7 bound to FKBP12 was only detected after cells were stimulated with activin, suggesting that FKBP12 functions in a complex with Smad7 after activation of the signal. 
FKBP12 associates with the N-terminal domain of Smad7 and recruits Smad7 to ALK4
In order to define the responsible domain of this interaction, we performed an in vitro interaction assay with GST-Smad7 deletion mutants (Fig. 4A) . HEK293 cells transfected with Flag-FKBP12 were lysed and subjected to the pull-down assay with GST-Smad7 deletion mutants. FKBP12 interacted with full-length Smad7 and weakly interacted with Smad7N but not with Smad7C (Fig. 4B, top panel) . These interactions were remarkably enhanced when cells were activated by coexpression with caALK4 mutant but not transfected with wt ALK4 (Fig. 4B, middle and lower panels) . This mutated (T206E) receptor, caALK4, shows constitutively high kinase activity and can activate the downstream signaling pathway in an activinindependent manner (Willis et al. 1996) . Since Smad7 is quickly induced after ligand stimulation and associates with the type I receptors to inhibit the signal, our results raise the possibility that FKBP12 bound again to ALK4 after prolonged activin treatment may function to recruit Smad7 to the receptor. To verify this hypothesis, we investigated the effect of FKBP12 on the association of Smad7 to ALK4. We repeated the GST pull-down assay with the HEK293 cell lysate that overexpressed 5 myc-caALK4 with or without FKBP12. ALK4 associated with the full-length and the N-terminal part of Smad7 (Fig. 4C, top panel) . When FKBP12 was overexpressed, ALK4 bound to the full-length Smad7 and Smad7N was remarkably increased (Fig. 4C , middle panel). ALK4 also bound to the C-terminal Smad7. However, treatment with FK506, which dissociates FKBP12 from ALK4, dramatically decreased the interaction of ALK4 with full-length Smad7 and Smad7N, although ALK4 still bound to Smad7C (Fig. 4C, bottom panel) . These results indicated that FKBP12 is able to enhance the association between ALK4 and Smad7 by the additional interaction of FKBP12 to the N-terminal of Smad7.
The effects of FKBP12 on the association of Smad7 with Smurf1 in vivo
Smad7 is known to recruit Smurf1, an E3 ubiquitin ligase, to the type I receptor to promote ubiquitination of the receptor (Kavsak et al. 2000 ). Since we showed that FKBP12 co-operates with Smad7 to inhibit the signaling, and enhances the association of Smad7 with ALK4, we next investigated whether FKBP12 affects the complex formation between Smad7, Smurf1, and ALK4. To do this, FKBP12 and Smurf1 bound to Smad7 were analysed by coimmunoprecipitation assay with 293T cells transfected with FKBP12, Smurf1, Smad7, and caALK4. Since overexpression of caALK4 activates the cellular activin-signaling pathway for a long period, this generates similar conditions as the later time-points described in Fig. 1 . As shown in Fig. 5A , the interaction between Smad7 and Smurf1 was not clearly affected by the overexpression of FKBP12, although FKBP12 was clearly associated with Smad7 (Fig. 5A, panel a, lane 4) . However, treatment of the cells with 250 nM FK506 for 4 h before harvest released FKBP12 from ALK4, and decreased the quantity of Smurf1 bound to Smad7 (Fig. 5A, panel a, lane 5) . Under these conditions, Smad7 was dissociated from ALK4 ( Fig. 5A, panel d, lane 5) . These results indicated that FKBP12 is an important factor for the assembly of Smurf1, Smad7, and ALK4. We also immunoprecipitated ALK4 and analyzed the amount of Smurf1, Smad7, and FKBP12 bound to ALK4. The amount of Smad7 and Smurf1 bound to ALK4 was remarkably increased by the transfection of FKBP12 (Fig. 5B, lane 3) . This interaction was weakened by the addition of FK506 (Fig. 5B, lane 4) . These results indicated that FKBP12 is an important factor for the formation of these complexes on the type I receptor. A point mutated FKBP12 (F36Y) lacks peptidyl-prolyl isomerase activity (Wiederrecht et al. 1992) . This mutant bound fairly weakly with Smad7. Overexpression of these mutants did not affect the interaction between Smurf1 and Smad7 (Fig. 5A, lane 6) .
The effects of FKBP12 on the ubiquitination of ALK4
Finally, we tested whether FKBP12 affects the ubiquitination of ALK4 induced by Smad7-Smurf1 complexes. HEK293T cells were transfected with FKBP12, Smad7, Smurf1, and ubiquitin together with caALK4, and the ubiquitinated proteins were immunoprecipitated. Ubiquitination of ALK4 was enhanced when the adaptor protein Smad7 and the E3 ligase Smurf1 were overexpressed (Fig. 6, lane 4) , as shown in previous studies . The level of ubiquitinated caALK4 was similar even though FKBP12 was further expressed (Fig. 6, lane 5) . However, the release of FKBP12 from ALK4 by the addition of FK506 decreased the ubiquitination of ALK4 (Fig. 6,  lane 6) . These results support the importance of FKBP12 for the ubiquitination of ALK4 by the Smad7-Smurf1 complex.
Discussion
In this study, we have demonstrated that FKBP12 functions not only as a secure switch in the absence of ligands, but also has an inhibitory effect after activation of signaling. We first noticed that FKBP12 dissociates from ALK4 after stimulation with activin for 1 h, where the activin signal can be fully propagated to the downstream target, Smad proteins. Thereafter, FKBP12 starts to associate again with ALK4 to negatively regulate activin signaling (Fig. 1) . This finding is consistent with the phosphorylation status of R-Smads and their localization in the nucleus as previously observed in TGF-signaling (Inman et al. 2002) . We confirmed that the overexpression of FKBP12 inhibits the activin-dependent transcriptional response ( Fig. 2A) , and that treatment with FK506, which releases endogenous FKBP12 from the type I receptor, activated the activin signaling.
Inhibitory Smads, Smad7 and Smad6, are the major feedback regulators in TGF-superfamily signaling (Hayashi et al. 1997 , Nakao et al. 1997 , Itoh et al. 1998 . Accordingly, we hypothesized that these Smad proteins might participate in the inhibitory functions of FKBP12 on activin signaling after prolonged ligand stimulation. Consequently, we showed that FKBP12 synergistically inhibits activin-dependent transcriptional response with Smad7, but not with Smad6 (Fig. 2B ). In addition, we found that FKBP12 associates with Smad7, especially when activin signaling is activated, and FKBP12 strengthens the interaction between Smad7 and ALK4 (Figs 3 and 4) . These findings raised the possibility that FKBP12 may play an important role in the recruitment of Smad7 to the type I receptor. Previous studies have demonstrated that the MH2 domain of Smad7 is important for its association with the type I receptors (Hayashi et al. 1997 , Souchelnytskyi et al. 1998 . However, another study has demonstrated that the N-terminal part of Smad7 does not interact with the TGF-type I receptor, but it enhanced the inhibitory activity of the Mad homology domain 2 (MH2) by facilitating the interaction of the MH2 domain with the receptor (Hanyu et al. 2001) . Very recently, Ogunjimi et al. (2005) have shown that the N-terminal domain of Smad7 stimulates Smurf activity by recruiting the E2 enzyme, UbcH7, to the HECT domain (homologous to E6-AP carboxyl terminus) of Smurf2. In our in vitro interaction assay, the N-terminal part of Smad7 associated with ALK4 weakly, and the interaction was remarkably enhanced when FKBP12 was overexpressed. We did not observe a clear interaction of Smad7 via its MH2 domain with activated type I receptor under normal conditions, but this interaction was distinctly observed when FKBP12 was released by the addition of FK506 (Fig. 4C) . These results suggest that FKBP12 or related proteins might function as a rigid partner of ALK4 in 293T cells, and Smad7 could be easily recruited to the type I receptor through FKBP12. We noticed that FKBP12 also associated with Smad6 in the mammalian two-hybrid assay (Fig. 3A) . However, this association was relatively weaker than that of Smad7, and Smad6 did not synergistically inhibit activin signaling with FKBP12 in the luciferase assay because Smad6 mainly inhibits BMP signaling (Hanyu et al. 2001) . We therefore focused the further study on the effect of FKBP12 on Smad7.
To further clarify the roles of FKBP12 in the inhibitory mechanism of Smad7 in activin signaling, we also tested the effect of FKBP12 on the recruitment of Smurf1 to ALK4. Interestingly, when FKBP12 was dissociated from ALK4 by the addition of FK506, the protein level of Smurf1 bound to Smad7 was decreased (Fig. 5A) , indicating that the FKBP12-ALK4 interaction is important for the recruitment of Smurf1 to Smad7. Another important inhibitory mechanism in activin signaling is the ubiquitination of the type I receptor induced by the Smad7-Smurf1 complex. As shown in Fig. 6 , dissociation of FKBP12 from ALK4 by FK506 treatment dramatically decreased the ubiquitination of the receptor. This indicates that FKBP12 is an essential factor for the ubiquitination of type I receptor. However, we failed to observe a clear enhancement of the ubiquitination of ALK4 by the overexpression of FKBP12. This might be due to sufficient amounts of endogenous FKBP12 or related proteins expressed in this cell line.
FKBP12 is a peptidyl-prolyl cis-trans isomerase, and recognizes a proline preceded by a leucine or similarly branched hydrophobic residue (Albers 1990 , Harrison & Stein 1990 . We tested whether the isomerase activity is required for the recruitment of Smad7 and Smurf1 to the receptor by using an FKBP12 mutant, F36Y, which lacks the enzyme activity. However, we could not see any clear effects on the complex formation with the mutants. The isomerase activity of FKBP12 may not be required for the recruitment of Smurf1 to Smad7.
Recent work has revealed the importance of endocytosis in TGF-family signaling. Although type I receptor activation occurs at the plasma membrane, downstream signaling through the Smads requires receptor internalization (Hayes et al. 2002 , Penheiter et al. 2002 , Di Guglielmo et al. 2003 . Ligand-induced internalization of TGF-receptor complexes occurs through two different internalization routes of the TGF-receptors (Di Guglielmo et al. 2003 , ten Dijke & Hill 2004 . Clathrindependent internalization into early endosomes promotes TGF-signaling, as Smad anchor for receptor activation (SARA) bound on phosphatidylinositol 3-phosphateenriched early endosomes presents Smad2 and Smad3 to the activated receptor complex. On the other hand, caveolae-mediated internalization is involved in the degradation of TGF-receptors. In caveolae, Smad7-Smurf complexes target TGF-receptors for polyubiquitination and proteasomal degradation. In this paper, we have shown that FKBP12 forms a complex with Smad7, promotes recruitment of Smurf1, and enhances degradation of ALK4. FKBP12 therefore presumably functions as an adaptor of the Smad7-Smurf1 complex on the receptor in the caveolae-dependent pathway to negatively regulate activin signaling. Since the inhibitory effects of FKBP12 in the activin transcriptional response are similar to that of TGF-, FKBP12 may play similar roles in other TGF-superfamily signalings.
FKBP12 also functions as a negative regulator of TGF-receptor endocytosis. Yao et al. (2000) used a fibroblast cell line expressing the chimeric TGFreceptor system and demonstrated that the receptor internalization was enhanced when FKBP12 binding to the chimeric type I receptor was prevented by rapamycin. Interestingly, despite the faster rate of internalization, the rate of ligand degradation was unchanged by rapamycin. We assume that rapamycin enhances not only ligand-dependent endocytosis and subsequent degradation of TGF-ligand but also induces disassembly of ubiquitination machinery as we demonstrated with FK506 in Figs 5 and 6. These complex effects of rapamycin might compensate for the degradation of TGF-ligand induced by this drug.
In summary, we propose a novel role of FKBP12 in activin signaling as summarized in Fig. 7 . FKBP12 functions as an adaptor protein for the efficient recruitment of the Smad7-Smurf1 complex to the activin type I receptor after prolonged activin treatment. FKBP12 seems to be a prerequisite molecule for proper regulation of activin signaling not only as a secure switch but also as an adaptor for Smad7 and Smurf1 to ALK4, which then promotes ubiquitination of the receptor to terminate the signal. 
